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Mitochondria function associated genes contribute to
Parkinson’s Disease risk and later age at onset
Kimberley J. Billingsley1,2, Ines A. Barbosa3, Sara Bandrés-Ciga2, John P. Quinn1, Vivien J. Bubb1, Charu Deshpande4, Juan A. Botia5,6,
Regina H. Reynolds 6, David Zhang6, Michael A. Simpson3, Cornelis Blauwendraat2, Ziv Gan-Or7,8,9, J. Raphael Gibbs2, Mike A. Nalls2,10,
Andrew Singleton2, International Parkinson’s Disease Genomics Consortium (IPDGC), Mina Ryten6 and Sulev Koks 11,12
Mitochondrial dysfunction has been implicated in the etiology of monogenic Parkinson’s disease (PD). Yet the role that
mitochondrial processes play in the most common form of the disease; sporadic PD, is yet to be fully established. Here, we
comprehensively assessed the role of mitochondrial function-associated genes in sporadic PD by leveraging improvements in the
scale and analysis of PD GWAS data with recent advances in our understanding of the genetics of mitochondrial disease. We
calculated a mitochondrial-speciﬁc polygenic risk score (PRS) and showed that cumulative small effect variants within both our
primary and secondary gene lists are signiﬁcantly associated with increased PD risk. We further reported that the PRS of the
secondary mitochondrial gene list was signiﬁcantly associated with later age at onset. Finally, to identify possible functional
genomic associations we implemented Mendelian randomization, which showed that 14 of these mitochondrial function-
associated genes showed functional consequence associated with PD risk. Further analysis suggested that the 14 identiﬁed genes
are not only involved in mitophagy, but implicate new mitochondrial processes. Our data suggests that therapeutics targeting
mitochondrial bioenergetics and proteostasis pathways distinct from mitophagy could be beneﬁcial to treating the early
stage of PD.
npj Parkinson’s Disease             (2019) 5:8 ; https://doi.org/10.1038/s41531-019-0080-x
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
movement disorder characterized pathologically by the death of
dopaminergic neurons in the substantia nigra (SN) and aggrega-
tion of α-synuclein protein (encoded by SNCA), within intraneur-
onal inclusions called Lewy bodies. The majority of PD cases are
apparently sporadic in nature (~95%). Aging is a major risk factor
for disease and due to population ageing the prevalence of PD is
predicted to increase rapidly, making the identiﬁcation of
therapeutic targets a high priority.1–3
Although there have been great advances in understanding
both the genetic architecture and cellular processes involved in
PD, the exact molecular mechanisms that underlie PD remain
unknown.1 However, it is suggested that PD has a complex
etiology, involving several molecular pathways, and understand-
ing these speciﬁc pathways will be key to establishing mechanistic
targets for therapeutic intervention. While several key pathways
are currently being investigated, including autophagy, endocy-
tosis, immune response, and lysosomal function,4–7 mitochondrial
function was the ﬁrst biological process to be associated with
PD.8,9
An interest in mitochondrial function and PD began with the
observation that exposure to the drug 1-methyl-4-phenyl-1,2,3,4-
tetrahydropyridine (MPTP) can cause rapid parkinsonism and
neuronal loss in the SN in humans, and that this is mediated
through inhibition of complex I of the mitochondrial electron
transport chain.7,10,11 Subsequent work suggested that individuals
with sporadic PD have reduced complex I activity not only in the
SN, but in other brain regions and peripheral tissues.12 Genetic
studies focusing on monogenic forms of PD provided further
support for the involvement of mitochondrial dysfunction in the
disease. Pathogenic mutations that lead to autosomal recessive
forms of PD have been reported in PINK1, PARK2, PARK7, CHCHD2,
and VPS13C and the proteins they encode are all now known to be
involved in the mitochondrial quality control system and in
particular mitophagy.13–16
Therefore, in this paper, we aim to comprehensively assess the
role of mitochondrial function in sporadic PD by leveraging
improvements in the scale and analysis of PD genome-wide
association study (GWAS) data with recent advances in our
understanding of the genetics of mitochondrial disease. The
availability of large-scale genome-wide association data in PD
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cases and the rapid identiﬁcation of genetic lesions that underlie
mitochondrial disease provide an opportunity to systematically
assess the role of genetic variability in mitochondrial linked genes
in the context of risk for PD.17 In this study we combine these new
resources with current statistical tools, such as polygenic risk
scoring and Mendelian randomization, to explore the role of
mitochondrial function in both PD risk and age at onset of disease
to obtain novel insights.
RESULTS
Common variation within mitochondria function genes
contributes to the heritable component of PD
The general workﬂow for the genetic analysis used in this study is
shown in Fig. 1. First, to study the importance of mitochondrial
function in sporadic PD, we investigated the heritability of PD
speciﬁcally within genomic regions that contained genes anno-
tated as important in mitochondrial function. The construction of
this annotation was driven by the principle that genomic regions,
which are known to be the sites of mutations in individuals with
rare mitochondrial diseases or are candidate regions for such
mutations provide the best evidence for involvement in mito-
chondrial function.
GCTA is a statistical method that estimates phenotypic variance
of complex traits explained by genome-wide SNPs, including
those not associated with the trait in a GWAS. Using GCTA,
heritability estimates were ﬁrst calculated for the four largest
IPDGC GWAS datasets, including all variants (WTCCC PD GWAS
(PMID:21044948), Spanish Parkinson’s (IPDGC) part2, NIA PD
GWAS (PMID:19915575), Dutch GWAS (PMID:21248740). Owing
to the low number of included cases, the heritability estimates in
the other IPDGC datasets were deemed less reliable. Consistent
with previous heritability estimates from both Keller et al.(24%)
and Chang et al. (21%), our random-effects meta-analysis for the
four datasets identiﬁed 23% (95% CI 12–34, p= 2.72E-05) pheno-
typic variance associated with all PD samples (Tables 1 and 2).
There was a high degree of consistency across the cohorts.
After establishing the consistency of our heritability estimates,
we next calculated heritability using only variants located within
genic regions speciﬁed as being of primary (n= 176) or secondary
(n= 1463) importance in mitochondrial function. Initially, to assess
the full contribution of the mitochondria pathway we ran the
analysis including and excluding the PD risk genes.6 However, as
shown in Supplementary Fig. 1 there was little difference overall in
the heritability estimates. Therefore, to only to catalog
mitochondria-speciﬁc genetic risk outside of known loci we
focused on the analysis excluding these genes. The heritability
estimate using a random-effects meta-analysis for the primary
gene list excluding the PD genes was estimated to be a modest
0.26% (95% CI −0.11–0.66, p= 0.166). However, the heritability
estimate using a random-effects meta-analysis for the secondary
list, namely genes implicated in mitochondrial function or
morphology, as well as disease, was estimated to be 1.67%
(95% CI −0.07–0.32, p= 0.041).
Mitochondria function-speciﬁc polygenic risk score is signiﬁcantly
associated with disease status
Next, we calculated PRS to capture the addictive effect of all
common variants within genes implicated in mitochondria
function on PD risk. PRS is a particularly powerful approach in
this context because it is able to efﬁciently incorporate informa-
tion from all hits, including sub-signiﬁcant hits, which may
nonetheless be etiologically relevant. Again, initially we ran the
analysis including and excluding the PD risk genes and the
comparison can be seen in Supplementary Fig. 2. However, to only
report novel associations we focused on the lists excluding the PD
risk genes.
Using this approach, the primary and secondary mitochondrial
genomic annotations were found to be signiﬁcantly associated
with PD disease status. Remarkably, the primary gene list
consisting of only 176 genes implicated in Mendelian mitochon-
drial disorders was associated with PD with an odds ratio of 1.12
per standard deviation increase in the PRS from the population
mean (random-effects p-value= 6.00E-04, beta= 0.11, SE= 0.03).
Fig. 1 Workﬂow of mitochondrial-function speciﬁc PD analysis
Table 1. Cohort-level heritability analysis for the primary and secondary mitochondrial gene lists
Primary Secondary
Heritability estimate SE of heritability estimate Heritability estimate SE of heritability estimate
WTCCC PD GWAS (PMID:21044948) 0.00321 0.00277 0.00563 0.00688
Spanish Parkinson’s (IPDGC) part2 0.00027 0.00314 0.00629 0.00932
NIA PD GWAS (PMID:19915575) 0.00945 0.00540 0.03616 0.01365
Dutch GWAS (PMID:21248740) 0.00000 0.00530 0.03562 0.01681
Reporting estimates for the WTCCC PD GWAS (PMID:21044948), Spanish Parkinson’s (IPDGC) part2, NIA PD GWAS (PMID:19915575), Dutch GWAS
(PMID:21248740) cohorts. Showing heritability estimates generated using GCTA and standard error of the estimates (SE)
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The secondary gene list, which also included genes implicated in
mitochondria function or morphology, was associated with PD
with a higher odds ratio of 1.28 per standard deviation increase in
the PRS from the population mean (random-effects p-value=
1.9E-22, beta= 0.25, SE= 0.03) (Fig. 2). Altogether, these analyses
not only provide further support for importance of mitochondrial
processes in PD, but potentially provide a tool for identifying PD
patients most likely to beneﬁt from treatments speciﬁcally
targeting mitochondrial function.
Mitochondria function-speciﬁc polygenic risk score is signiﬁcantly
associated with later age at onset
Although multiple lines of evidence point to the importance of
mitochondrial dysfunction as a primary cause of PD, impaired
mitochondrial dynamics appears to be common to a wide range
of neurodegenerative diseases, including Huntington’s dis-
ease,18,19 amyotrophic lateral sclerosis,20,21 and Alzheimer’s
disease.22–25 The latter suggests that even when impaired
mitochondrial function is not the primary event in disease
pathogenesis, it is a common outcome and could contribute to
disease progression. We sought to test this hypothesis by
investigating the importance of common variation within our
mitochondrial gene lists in determining the age at onset of PD
(AAO). Given the signiﬁcant lag period between PD pathophysiol-
ogy and symptoms, AAO was used as an indirect measure of
disease progression. This analysis was performed using PRS since
it has been consistently found to be the main genetic predictor of
AAO6,26–28 with higher genetic risk scores being signiﬁcantly
associated with an overall trend for earlier AAO of disease. While
the primary mitochondrial gene list was not signiﬁcantly
associated with AAO of disease, the secondary gene list was
correlated with AAO. Contrary to expectation, the cumulative
burden of common variants within the 1326 genes comprising the
PRS for PD risk were positively correlated with AAO of PD. After
meta-analyzing, we found that each 1SD increase in PRS, led to a
0.55 year increase in the AAO of disease (summary effect= 0.211,
95% CI (0.141–0.970),|2= 68.49%, p-value= 9.00E-03, Fig. 3). As
the forest plots demonstrate, although there was a relatively high
heterogeneity across studies, the directionality and magnitude of
effect on AAO were in concordance with the meta-analysis with
the exception of the Oslo cohort. This ﬁnding could suggest that
ﬁrstly, disease causation and progression are genetically separable
processes in PD and that secondly the role of mitochondrial
dysfunction in PD is likely to be highly complex with multiple
distinct mitochondrial processes likely to be involved at different
disease stages.
Mendelian randomization suggests potential causal association of
14 novel mitochondria function genes with PD risk
Given the robust evidence for the involvement of mitochondrial
function in sporadic PD, next we used two-sample MR analysis to
identify speciﬁc genes likely to be important in PD risk. MR uses
genetic variants to identify if an observed association between a
risk factor and an outcome is consistent with causal effect.29 This
Table 2. Summary of random-effects meta-analysis for the primary and secondary mitochondrial gene lists
Heritability estimate
from random-effects
Lower 95%
conﬁdence interval
Upper 95%
conﬁdence interval
p-value from
random effects
Heterogeneity of variance
from random effects (%)
Heterogeneity
p-value
All SNPs 0.2313 0.1233 0.3393 2.72E-05 0.0100 3.00E-03
Primary 0.0026 −0.0011 0.0062 1.66E-01 0.0000 4.85E-01
Secondary 0.0167 0.0007 0.0328 4.10E-02 0.0001 9.63E-02
Here, we show the random-effects meta-analysis of heritability estimates for all SNPs in the genome (All SNPs), estimate calculated with for the SNPs within the
primary mitochondria list genes (Primary), and the SNPs within the secondary mitochondria list genes (Secondary)
Fig. 2 Forest plots of PRS for Parkinson’s Disease across cohorts. Random effect meta-analysis results are shown as red diamonds and ﬁxed
effects are shown as blue, with the centerline of each diamond representing the summary PRS for that dataset. IPDGC NeuroX= (Nalls et al.
2015, PMID:25444595), OSLO=Oslo Parkinson’s Disease Study, PDBP= Parkinson’s Disease Biomarker’s Program, PPMI= Parkinson’s
Progression Markers Initiative, Baylor= Baylor College of Medicine/University of Maryland, German GWAS= (PMID:19915575), VANCE=
Vance (dbGap phs000394)
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method has been implemented in several recent genetic studies
to identify association between expression quantitative trait loci
(QTL), to more accurately nominate candidate genes within risk
loci. Therefore, for this study, in the aim of identifying whether
changes in expression of mitochondria function genes are
potentially causally related to PD risk, two-sample MR was
implemented.
Since we wanted to identify novel associations, we excluded
genes already linked to PD through the most recent GWAS meta-
analysis.6 This resulted in the exclusion of 31 genes linked to
mitochondrial function and in linkage disequilibrium with the top
PD risk variants. Analysis of the remaining 1432 genes (generated
by combining the primary and secondary gene lists) resulted in
the identiﬁcation of 14 novel genes linked to mitochondrial
function and causally associated with PD risk (Table 3). Of the 14
genes, the expression of ﬁve genes (CLN8, MPI, LGALS3, CAPRIN2,
and MUC1) was positively associated with PD risk in blood.
Similarly, in brain PD risk was associated with increased expression
of ATG14, E2F1, and EP300 in brain. However, negative associations
in brain and blood expression were observed for MRPS34 and
PTPN1 and LMBRD1, respectively. Finally, elevated methylation of
FASN in the brain was found to be positively associated with PD
risk but elevated methylation of CRY2 was found to be inversely
correlated.
Six of the fourteen novel PD risk genes we identiﬁed (CLN8,
EP300, LMBRD1, MPI, MRPS34, and MUC1) are already associated
with a monogenic disorder (Table 3). We noted that neurological
abnormalities were a feature of the condition in ﬁve of the six
cases with Combined Oxidative Phosphorylation Deﬁciency 32
due to biallelic mutations in MRPS34 being perhaps of particular
interest. In common with PD, this condition is associated with
abnormalities of movement, including dystonia and choreoathe-
toid movements. Mutations causing this condition result in
decreased levels of MRPS34 protein causing destablization of the
small mitochondrial ribosome subunit and suggesting the
involvement of mitochondrial processes distinct from mitophagy
and mitochondrial homeostasis in PD. In this context, it is
noteworthy that MRPL43, another nuclear gene encoding for a
component of the large mitochondrial ribosome subunit is also
highlighted by the MR analysis. Thus, this analysis not only
enabled us to identify speciﬁc genes of interest, but also pointed
to the role of multiple mitochondrial processes in PD distinct from
mitophagy.
Exploring the expression of the novel mitochondria risk genes
provides additional support for their role in PD
We leveraged publicly available cell-speciﬁc and tissue-speciﬁc
gene expression data to investigate the 14 mitochondria genes
implicated in PD through MR. First, we used enrichment-weighted
cell-type enrichment (EWCE) to determine whether the expression
of mitochondrial PD-associated genes (as identiﬁed through MR
and described above, n= 14) was enriched within a speciﬁc cell-
type class or their subtypes. No signiﬁcant enrichment of these
genes was found in any of the tested neuronal and glial cell-type
classes (Supplementary Table 6 and Supplementary Fig. 3). Next,
we used co-expression network analysis to identify possible
functional interactions between the 14 novel mitochondrial genes
identiﬁed through MR and genes implicated in monogenic forms
of PD. We found that ﬁve of the 14 genes assessed, CLN8, FASN,
MPI, MRPL43, and MRPS3, were highly co-expressed with at least
one gene already implicated in monogenic PD in multiple brain
regions ( > 3 brain regions, Supplementary Table 7). Interestingly,
in the case of CLN8, MRPL43, and MRPS4, our novel genes were co-
expressed with a monogenic PD gene already implicated in
mitochondrial function such as PARK7. Furthermore, with the
exception of CLN8 (FASN, MPI, MRPL43 and MRPS3), the novel
mitochondrial gene was assigned to a co-expression module
enriched for neuronal markers (Supplementary Table 8).
DISCUSSION
We ﬁrst demonstrate that a proportion of the “missing heritability”
of sporadic PD can be explained by additive common genetic
variation within genes implicated in mitochondrial function, even
after exclusion of genes previously linked to PD through linkage
disequilibrium with the top risk variants.4–6,30–34 We identify that
the overall heritability of PD is approximately 23% (Table 2) and
that when heritability is calculated for the secondary gene list
regions alone we can attribute around 7% of the overall
heritability (23%) to common variation within the mitochondria
function associated genes. Although this initially looks like a low
estimate, to put this into context, when heritability was calculated
in the most recent meta-analysis using the top PD risk hits, this
estimate explained only 26–36% of the overall heritability.6 In
addition, using PRS, which efﬁciently incorporates information
from sub-signiﬁcant hits, we showed that cumulative small effect
variants within only 196 genes linked to monogenic mitochondrial
disease signiﬁcantly associated with increased PD risk (with odds
ratios of 1.12 per standard deviation increase in PRS from the
population mean). These ﬁndings are important for two main
reasons. Firstly, given that risk proﬁling performed in the recent
PD meta-analysis did not identify a signiﬁcant association with
mitochondrial function.4–6,17,30–34 Secondly, since the primary
gene list consisted solely of the 196 genes mutated in monogenic
mitochondrial disorders, this analysis highlights the increasingly
close relationship between Mendelian and complex disease.7
In order to maximize the utility of this study, we used MR, which
identiﬁed 14 speciﬁc mitochondrial genes of interest with putative
functional consequences in PD risk. We found that although a
number of the genes we identiﬁed are clearly linked to known PD-
related pathways, such as lysosomal dysfunction in the case of
CLN8 and LMBRD1 or autophagy in the case of ATG14, others
appeared to point towards new processes. In particular, this
analysis highlighted the mitochondrial ribosome through the
identiﬁcation of the genes, MRPL43 and MRPS34, encoding
components of the large and small mitochondrial ribosome
subunits, respectively. Interestingly, biallelic mutations in MRPS34
are known to cause a form of Leigh syndrome, characterized by
Fig. 3 Forest plots of PRS for the age at onset of Parkinson’s Disease
across cohorts. Random effect meta-analysis results are shown as
red diamonds and ﬁxed effects are shown as blue, with the
centerline of each diamond representing the summary PRS for that
dataset. OSLO=Oslo Parkinson’s Disease Study, PDBP= Parkinson’s
Disease Biomarker’s Program, PPMI= Parkinson’s Progression Mar-
kers Initiative, German GWAS= (PMID:19915575), VANCE= Vance
K.J. Billingsley et al.
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neurodegeneration in infancy with dystonia and choreoathetoid
movements due to basal ganglia dysfunction. Furthermore, we
note that a recent study that utilized whole exome sequencing
(WES) data from two PD cohorts to investigate35,36 rare variation in
nuclear genes associated with distinct mitochondrial processes,
not only provided support for the involvement of mitochondrial
function in sporadic PD, but also identiﬁed the gene, MRPL43,
which encodes a component of the large mitochondrial ribosomal
subunit.37 Interestingly, MRPL43 and MRPS34 were amongst ﬁve
genes, which were also highly co-expressed in human brain with
genes already known to cause monogenic forms of PD. Whereas
MRPL43 and MRPS34 were highly co-expressed with PARK7 in
modules enriched for neuronal markers, FASN and MPI were co-
expressed with ATP13A2, and CLN8 was located in modules
containing FBXO7 and enriched for oligodendrocyte markers.
While this form of analysis does not provide information at the
single-cell level, it points to the possibility of pathway interactions
between these gene sets. However, most importantly it implicates
entirely distinct mitochondrial processes in PD risk.
Finally, and perhaps most remarkably using our mitochondrial
gene lists we observe clear differences between disease causation
and AAO in PD. Although PRS of the primary mitochondrial gene
list was not signiﬁcantly associated with AAO, the PRS of the
secondary mitochondrial gene list was positively correlated (p-
value= 3.6E-05), indicating association with later age at onset.
However, given these ﬁndings it seems plausible that some
mitochondrial processes may contribute to PD risk. Thus, this
analysis is consistent with the ﬁndings of the most recent and
largest AAO PD GWAS, which reported that not all the well-
established risk loci are associated with AAO and suggested a
different mechanisms for PD causation and AAO.38 This has also
been shown in previous studies that have shown no association of
risk loci with AAO in sporadic PD.35,39
Although in this study we have comprehensively analyzed the
largest PD datasets currently available with very speciﬁc and
inclusive mitochondrial function gene lists, there are a number of
limitations to our analyses. Firstly, there was a relative amount of
heterogeneity in AAO within the AAO GWAS studies used. This
was due to certain cohorts AAO being self-reported and other
cohorts speciﬁcally recruiting younger onset cases. Nonetheless,
the highly signiﬁcant p-value we obtain for the association
mitochondrial genes and AAO of PD (p-value= 3.56E-05) and the
recognized importance of mitochondrial function in aging would
suggest that this ﬁnding is likely to be robust. Furthermore, it is
important to recognize that our understanding of mitochondrial
biology is far from complete and this is made evident by the fact
that many individuals with probable genetic forms of mitochon-
drial disease remain undiagnosed. This in conjunction with the
fact we also removed the mitochondria function-associated genes
that are known risk hits (such as SNCA), suggests that our analysis
likely represents an underestimate of the overall contribution of
the mitochondria pathway to sporadic PD. This underestimate is
illustrated in Supplementary Figs. 1 and 2, which shows that
heritability estimates and PRS scores are higher when the PD risk
genes are included. However, we note that our ultimate goal for
this study was to catalog mitochondria-speciﬁc genetic risk
outside of known risk loci, which we have subsequently reported.
Another possible limitation of this present study is that the
statistical tools we have used in these analyses are currently
limited. For example, MR ultimately relies on the availability of
sufﬁcient quantities of high-quality eQTL data. However, as there
is a future focus to; increase dataset sample size, report and
characterize phenotypes such as AAO more accurately and
continue to increase the number of identiﬁed mitochondrial
disease and function genes, we will be able to further explore the
role of speciﬁc mitochondrial processes in more detail and identify
their distinct contribution to disease causation and progression. In
regard to the MR nominated genes in particular, further follow-up
functional studies will be crucial to validate how these genes
contribute to disease risk. Finally, it is possible that our focus on
one speciﬁc pathway could infer a selection bias to our analyses.
However, the fact that our results are consistent across cohorts
and the fact that this signiﬁcant association is observed in multiple
tests, adds validity to our data. In light of this, however, a large-
scale unbiased approach should be the focus of future pathway
related studies to avoid this potential bias, although this will be
difﬁcult given the scope of work and sample size needed.
In summary, in this study we provide robust evidence for the
involvement of mitochondrial processes in sporadic PD, as
opposed to its deﬁned and well-established role in the monogenic
forms of the disease. In relation to the 14 novel mitochondrial
function genes that we have identiﬁed, our data suggests that it is
not only mitochondrial quality control and homeostasis, which
contributes to PD risk but other key mitochondrial processes, such
as the function of mitochondrial ribosomes, mirroring the
biological complexity of mitochondrial disorders. Thus, this study
opens the way for the identiﬁcation of novel drug targets in PD
causation and progression.
METHODS
Samples and quality control of IPDGC datasets
All genotyping data was obtained from previously generated IPDGC
datasets, consisting of 41,321 individuals (18,869 cases and 22,452
controls) of European ancestry. For the IPDGC datasets all participants
donated DNA samples and provided informed consent for participation in
genetics studies, which was approved by the local ethic committee for
each of the datasets used (National Institutes of Health, Department of
Health and Human Services; project ZO1 AG000949). Detailed demo-
graphic and clinical characteristics are given in Supplementary Table 1 and
are explained in further detail in refs. 6,38 along with detailed quality
control (QC) methods. For sample QC, in short, individuals with low call
rate ( < 95%), discordance between genetic and reported sex, hetero-
zygosity outliers (F-statistic cutoff of >−0.15 and < 0.15) and ancestry
outliers (+ /− 6 standard deviations from means of eigenvectors 1 and 2
of the 1000 Genomes phase 3 CEU and TSI populations from principal
components40) were excluded. Further, for genotype QC, variants with a
missingness rate of > 5%, minor allele frequency < 0.01, exhibiting
Hardy–Weinberg Equilibrium (HWE) < 1E-5 and palindromic SNPs were
excluded. Remaining samples were imputed using the Haplotype
Reference Consortium (HRC) on the University of Michigan imputation
server under default settings with Eagle v2.3 phasing based on reference
panel HRC r1.1 2016.41,42
Curation of genes implicated in mitochondrial disorders and
associated with mitochondrial function
Gene lists were built to encompass different levels of evidence for
involvement of the respective protein products in disease phenotypes that
relate to mitochondrial function. The list of genes implicated in genetic
mitochondrial disorders (“primary” gene list, n= 196) has the most
stringent criteria of evidence that the respective genes is related to
mitochondrial dysfunction. It consists of 102 nuclear genes listed in
MITOMAP (downloaded 2015) and 94 sourced from literature review as
containing mutations that cause with mitochondrial disease.
The list of genes implicated in mitochondrial function (“secondary” gene
list, n= 1487) was constructed using the OMIM API to identify all genes for
which the word “mitochondria” (or derivatives) appeared in the free-text
description, and by combining this information with MitoCarta v2.0 genes
with no OMIM phenotype. This therefore gathered a list of plausible
biological candidate genes, i.e., genes that are functionally implicated in
mitochondrial function and morphology for which we may lack genetic
evidence for mitochondrial disease association.
Next, to identify novel PD-associated genes, the 349 genes identiﬁed to
be in LD with the PD risk variants of interest in the most recent PD meta-
analysis6 were removed from both lists (removed genes listed in
Supplementary Table 2). The ﬁnal “primary” and “secondary” gene lists
are given in Supplementary Table 3 and Supplementary Table 4 and
following the removal the PD-associated genes were n= 178 and n=
1328, respectively.
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Cohort-level heritability estimates and meta-analysis
Genome-wide complex trait analysis (GCTA) was used to calculate
heritability estimates for the four largest IPDGC cohorts (WTCCC PD GWAS
(PMID:21044948), Spanish Parkinson’s (IPDGC) part2, NIA PD GWAS
(PMID:19915575), Dutch GWAS (PMID:21248740) using non-imputed
genotyping data for all variants within both mitochondria gene lists using
the same workﬂow as in ref. 43 Genetic relationship matrices were
calculated for each dataset to identify the genetic relationship between
pairs of individuals. Genetic relationship matrices were then input into
restricted maximum likelihood analyses to produce estimates of the
proportion of phenotypic variance explained by the SNPs within each
subset of data. Principal components (PCs) were generated for each
dataset using PLINK (version 1.9). In order to adjust for factors accounting
to possible population substructure, the top 20 generated eigenvectors
from the PC analysis, age, sex, and prevalence were used as basic
covariates. Disease prevalence standardized for age and gender based on
epidemiological reports was speciﬁed at 0.002.43–47 Summary statistics
from these estimates were produced for all four datasets and were
included in the meta-analyses. Random-effects meta-analysis using the
residual maximum likelihood method was performed using R (version
3.5.1) package metafor to calculate p-values and generate forest plots.48
Risk proﬁles versus disease status and age at onset
Previous risk proﬁling methods have calculated polygenic risk scores (PRS)
using only variants that exhibit genome-wide signiﬁcant associated with
disease risk. However, in the most recent PD meta-analysis, it is shown that
using variants at thresholds below genome-wide signiﬁcance improves
genetic predictions of disease risk.6,43 Mirroring this workﬂow, but instead
using only variants within gene regions outlined in both the primary and
secondary gene lists, the R package PRsice2 was used to carry out PRS
proﬁling in the standard weighted allele dose manner. In addition, PRsice2
performs permutation testing and p-value aware LD pruning to facilitate
identifying the best p-value threshold for variant inclusion to construct the
PRS. External summary statistics utilized in this phase of analysis included
data from leave-one-out meta-analyses (LOOMAs) that exclude the study
in which the PRS was being tested, avoiding overﬁtting/circularity to some
degree. LD clumping was implemented under default settings (window
size= 250 kb, r2 > 0.1) and for each dataset 10,000 permutations of
phenotype-swapping were used to generate empirical p-value estimates
for each GWAS derived p-value threshold ranging from 5E-08 to 0.5, at a
minimum increment of 5E-08. Each permutation test in each dataset
provided a Nagelkerke’s pseudo r2 after adjustment for an estimated
prevalence of 0.005 and study-speciﬁc PCs 1–5, age and sex as covariates.
GWAS derived p-value threshold with the highest pseudo r2 was selected
for further analysis. Summary statistics were meta-analyzed using random
effects (REML) per study-speciﬁc dataset using PRSice2.49 For the age at
onset risk proﬁling, the same workﬂow was followed, however instead, age
at onset was used as a continuous variable, as previously reported.38 To
remove possible confounders that could possibly drive a false association
with age we removed APOE and FOXO3, which are general markers for
aging.50
Mendelian randomization to explore possible causal effect of
mitochondria function genes
Both mitochondria gene lists were combined, and all genes already
associated with PD (i.e., that have been identiﬁed to be in LD with PD risk
loci in the last meta-analysis) were removed, leaving 1432 unique
mitochondria function gene regions.
We utilized four large-scale methylation and expression datasets
through the summary-data-based Mendelian randomization (SMR)
(http://cnsgenomics.com/software/smr) resource. Summary statistics were
compared to PD outcome summary statistics for the mitochondria variants
of interest (extracted from refs. 4–6,30–34) to identify possible association
using the R package TwoSampleMR.
Tissues were selected based on their relevance to the pathobiology of
PD, which ultimately consisted of tissues from ten brain regions, whole
blood, skeletal muscle, and nerve (a full list of the tissues utilized can be
found in Supplementary Table 5). For the methylation QTLs “middle age”
data was used, which was the oldest available time point. For each
mitochondria function variant of interest (considered here the instru-
mental variable), wald ratios were generated for each variable that tagged
a cis-QTL (probes within each gene and meeting a QTL p-value of at least
5E-08 in the original QTL study) and for a methylation or expression probe
with a nearby gene. Using the default SMR protocols, linkage pruning and
clumping were implemented. Finally, for each dataset p-values were
adjusted by false discovery rate to account for multiple testing.
Co-expression network analysis
Co-expression network analysis was used to determine whether mitochon-
drial genes associated with PD using the SMR analysis are co-expressed
with genes associated with monogenic forms of PD in human brain. This
analysis was performed by using GTEx V6 gene expression data51 to
generate co-expression networks for each of the 13 brain tissues included
within the GTEx study. The raw FPKM (Fragments Per Kilobase of transcript
per Million mapped reads) values were corrected for known batch effects,
age at death, sex and post-mortem interval, as well as unknown effects.
The unknown effects were detected with the Surrogate Variable Analysis
(SVA) R Package52 and correction was performed using ComBat53. The
resulting residuals were used to create a signed network using the
blockwiseConsensusModules R function from the WGCNA R package54 for
each of the 13 tissues. Next, the modules obtained in each of the 13
networks were assigned to cell types using the user List Enrichment R
function implemented in the WGCNA R package, which measures
enrichment between module-assigned genes and deﬁned brain-related
lists using a hypergeometric test. The same approach was used to annotate
modules with Gene Ontology, REACTOME55 and KEGG56 terms.
Expression-weighted cell-type enrichment (EWCE): evaluating
enrichment of mitochondrial genes associated with PD risk
Expression-weighted cell-type enrichment (EWCE) (https://github.com/
NathanSkene/EWCE) (EWCE) was used to determine whether mitochon-
drial genes associated with PD using the MR analysis have higher
expression within a particular cell type than expected by chance. The input
for the analysis was (1) neuronal and glial clusters of the central nervous
system (CNS) identiﬁed in the Linnarsson single-cell RNA sequencing
dataset (amounting to a subset of 114 of the original 265 clusters
identiﬁed) (http://mousebrain.org/) and (2) our list of mitochondrial genes
highlighted through the MR analysis (see Supplementary Table 6 for the
full list of Linnarsson CNS neuronal clusters used).
For each gene in the Linnarsson dataset, cell-type speciﬁcity was
estimated (the proportion of a gene’s total expression in one cell-type
compared to all cell types) using the ‘generate.celltype.data’’ function of
the EWCE package. EWCE with the target list was run with 100,000
bootstrap replicates, which were sampled from a background list of genes
that excluded all genes without a 1:1 mouse:human ortholog. In addition,
transcript length and GC-content biases were controlled for by selecting
bootstrap lists with comparable properties to the target list. The analysis
was performed using major cell-type classes (e.g., “telencephalon
inhibitory interneurons”, “telencephalon projecting excitatory neurons”,
etc.) and subtypes of these classes (e.g., TEINH6 [“Interneuron-selective
interneurons, cortex/hippocampus”], TEINH7 [“Interneuron-selective inter-
neurons, hippocampus”] etc.). Data are displayed as standard deviations
from the mean, and any values < 0, which reﬂect a depletion of expression,
are displayed as 0. p-values were corrected for multiple testing using the
Benjamini–Hochberg method over all cell types and gene lists displayed.
OMIM data
Phenotype relationships and clinical synopses of all OMIM genes were
downloaded from http://api.omim.org on the 29th of May 2018. OMIM
genes were ﬁltered to exclude provisional, non-disease and susceptibility
phenotypes retaining 2898 unique genes that were conﬁdently associated
to 4034 Mendelian diseases. The phenotypic information relating to all
genes associated with mitochondrial disorders was collated.
DATA AVAILABILITY
For all datasets included in this study GWAS summary statistics are available at:
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